Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections.
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Injection drug use provides an efficient mechanism for transmitting bloodborne viruses, including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Effective targeting of resources for prevention of HIV and HCV infection among persons who inject drugs (PWID) is based on knowledge of the population size and disparity in disease burden among PWID. This study estimated the number of PWID in the United States to calculate rates of HIV and HCV infection. METHODS: We conducted meta-analysis using data from 4 national probability surveys that measured lifetime (3 surveys) or past-year (3 surveys) injection drug use to estimate the proportion of the United States population that has injected drugs. We then applied these proportions to census data to produce population size estimates. To estimate the disease burden among PWID by calculating rates of disease we used lifetime population size estimates of PWID as denominators and estimates of HIV and HCV infection from national HIV surveillance and survey data, respectively, as numerators. We calculated rates of HIV among PWID by gender-, age-, and race/ethnicity. RESULTS: Lifetime PWID comprised 2.6% (95% confidence interval: 1.8%-3.3%) of the U.S. population aged 13 years or older, representing approximately 6,612,488 PWID (range: 4,583,188-8,641,788) in 2011. The population estimate of past-year PWID was 0.30% (95% confidence interval: 0.19 %-0.41%) or 774,434 PWID (range: 494,605-1,054,263). Among lifetime PWID, the 2011 HIV diagnosis rate was 55 per 100,000 PWID; the rate of persons living with a diagnosis of HIV infection in 2010 was 2,147 per 100,000 PWID; and the 2011 HCV infection rate was 43,126 per 100,000 PWID. CONCLUSION: Estimates of the number of PWID and disease rates among PWID are important for program planning and addressing health inequities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The proportion of candidemia patients with an IDU history is much higher than the estimated <1% of the entire U.S. population with a history of IDU during the previous 12 months (55)”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [55]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 2×
“5% population proportion of PWID in Puerto Rico, Puerto Rico population totals from census data [16], and the estimated number of PWID living with diagnosed HIV infection in Puerto Rico in 2010 from CDC’s HIV case surveillance data [5].”
BackgroundMethodFixed-and random-effects models in meta-analysis.
Hedges, L. V., & Vevea, J. L. (1998) · Psychological Methods · doi:10.1037/1082-989x.3.4.486 · Cited by 2,977 · cited 1×
“We selected random effects models for our analyses because the models assume the studies are a random sample [15], a type of inference that fits the purpose of our study.”
MethodThe Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
(1998) · PsycEXTRA Dataset · doi:10.1037/e547602006-001 · Cited by 1,213
[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y. T., Holtzman, D. J., Teo, C., Jewett, A., Baack, B. N., Rein, D. B., Patel, N., et al. (2012) · PubMed · Cited by 991
Self-citationLyons, S. J., Johnson, A. S., Hu, X., Yu, C., Jin, C., Wu, B., Li, J., Chong, M., Hawkins, D., Wang, S., et al. (2017) · Cited by 636
Mohaghegh, H. (2014) · Journal of Liver · doi:10.4172/2167-0889.1000147 · Cited by 609
The estimated prevalence and incidence of HIV in 96 large US metropolitan areas.
Holmberg, S. D. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.5.642 · Cited by 539 · cited 1×
“PWID among the nation as a whole and for large metropolitan areas [7–10].”
Background
Cited by
Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses
Sullivan, P. S., Satcher Johnson, A., Pembleton, E. S., Stephenson, R., Justice, A. C., Althoff, K. N., Bradley, H., Castel, A. D., Oster, A. M., Rosenberg, E. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00395-0 · Cited by 355
Lifetime risk of a diagnosis of HIV infection in the United States
Hess, K. L., Hu, X., Lansky, A., Mermin, J., & Hall, H. I. (2017) · Annals of Epidemiology · doi:10.1016/j.annepidem.2017.02.003 · Cited by 356
“and have a very high rate of receiving a diagnosis of HIV infection compared to males in other risk groups: 672 per 100,000 (6) compared to 49 per 100,000 male PWID (4) and 3.”
BackgroundInfluentialSelf-citationToda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., et al. (2019) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6808a1 · Cited by 198
“Echinocandins 888 (55) 582 (57) 137 (40) 191 (38) 1,798 (51)”
BackgroundInfluentialEstimated Number of People Who Inject Drugs in the United States
Bradley, H., Hall, E. W., Asher, A., Furukawa, N. W., Jones, C. M., Shealey, J., Buchacz, K., Handanagic, S., Crepaz, N., & Rosenberg, E. S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac543 · Cited by 168
Self-citationHIV Incidence, Prevalence, and Undiagnosed Infections in U.S. Men Who Have Sex With Men
Singh, S., Song, R., Johnson, A. S., McCray, E., & Hall, H. I. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2082 · Cited by 142
“Rates for transmission categories were calculated by using published population size estimates as denominators (7, 19, 20).”
MethodTransition from injecting opioids to smoking fentanyl in San Francisco, California
Kral, A. H., Lambdin, B. H., Browne, E. N., Wenger, L. D., Bluthenthal, R. N., Zibbell, J. E., & Davidson, P. J. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109003 · Cited by 145
Biello, K. B., Bazzi, A. R., Mimiaga, M. J., Biancarelli, D. L., Edeza, A., Salhaney, P., Childs, E., & Drainoni, M. (2018) · Harm Reduction Journal · doi:10.1186/s12954-018-0263-5 · Cited by 145
“Introduction People who inject drugs (PWID) are disproportionately affected by HIV/AIDS [1], accounting for 7–10% of new HIV infections in the USA annually [1, 2].”
BackgroundJackson, K. A., Bohm, M. K., Brooks, J. T., Asher, A., Nadle, J., Bamberg, W. M., Petit, S., Ray, S. M., Harrison, L. H., Lynfield, R., et al. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6722a2 · Cited by 139
“population aged ≥13 years who injected drugs in the previous year for 2011 (9).”
Riley, W., Schwei, M. J., & McCullough, J. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01252.x · Cited by 132
Walters, S. M., Reilly, K. H., Neaigus, A., & Braunstein, S. (2017) · Harm Reduction Journal · doi:10.1186/s12954-017-0166-x · Cited by 133
The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses
Mahmud, S., Akbarzadeh, V., & Abu-Raddad, L. J. (2018) · Scientific Reports · doi:10.1038/s41598-017-18296-9 · Cited by 130
Bazzi, A. R., Biancarelli, D. L., Childs, E., Drainoni, M., Edeza, A., Salhaney, P., Mimiaga, M. J., & Biello, K. B. (2018) · AIDS Patient Care and STDs · doi:10.1089/apc.2018.0126 · Cited by 128
“Two key themes emerged regarding PrEP knowledge and interest: (1) accurate PrEP knowledge was low, in part, due to marketing focused on other risk populations and healthcare providers’ lack of time and unwillingness to discuss PrEP with PWID; (2) PrEP interest was tied to prior PrEP knowledge and HIV risk perceptions,…”
BackgroundQuinn, K., Boone, L., Scheidell, J. D., Mateu‐Gelabert, P., McGorray, S. P., Beharie, N., Cottler, L. B., & Khan, M. R. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.09.021 · Cited by 120
“Author Disclosures Role of Funding Source This work was supported by National Institute on Drug Abuse (NIDA) study R01DA036414: Longitudinal Study of Trauma, HIV Risk, and Criminal Justice Involvement and The Center for Drug Use and HIV/HCV Research (CDUHR) grant P30DA011041.”
MethodInfluentialBroz, D., Wejnert, C., Phạm, T. T. H., DiNenno, E. A., Heffelfinger, J. D., Cribbin, M., Krishna, N. K., Teshale, E. H., & Paz‐Bailey, G. (2014) · PubMed · Cited by 109
Self-citationKral, A. H., & Davidson, P. J. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.06.010 · Cited by 111
“is 2% and 43%, respectively.(2) With the U.”
BackgroundSee, I., Gokhale, R. H., Geller, A. I., Lovegrove, M. C., Schranz, A. J., Fleischauer, A. T., McCarthy, N. L., Baggs, J. M., & Fiore, A. E. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa149 · Cited by 88
“Using the 2011 estimate of number of those who had injected drugs in the past year [29] nationally yielded an estimate of 155 000–540 000 PWID with a skin or soft-tissue infections in the past year.”
BackgroundMethodSexual risk behaviors and STDs among persons who inject drugs: A national study
Brookmeyer, K. A., Haderxhanaj, L. T., Hogben, M., & Leichliter, J. S. (2019) · Preventive Medicine · doi:10.1016/j.ypmed.2019.105779 · Cited by 84
“3%) of persons over the age of 12 years had ever injected drugs (Lansky et al., 2014).”
BackgroundRapoport, A. B., Fischer, L. S., Santibanez, S., Beekmann, S. E., Polgreen, P. M., & Rowley, C. F. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy132 · Cited by 76
“6 million people have injected drugs during their lifetime [4].”
BackgroundRacialized risk environments in a large sample of people who inject drugs in the United States
Cooper, H. L. F., Linton, S. L., Kelley, M. E., Ross, Z., Wolfe, M. E., Chen, Y., Zlotorzynska, M., Hunter-Jones, J. J., Friedman, S. R., Jarlais, D. D., et al. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.07.015 · Cited by 80
“…stark in the United States (US), where HIV prevalence is six and eleven times higher among Latino and non-Hispanic black PWID, respectively, than among non-Hispanic white PWID (Centers for Disease Control and Prevention 2006, Laffoon, Satcher Johnson et al. 2011, Lansky, Finlayson et al. 2014).”
BackgroundSelf-citationBarocas, J. A., Tasillo, A., Yazdi, G. E., Wang, J., Vellozzi, C. J., Hariri, S., Isenhour, C. J., Randall, L. M., Ward, J. W., Mermin, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy098 · Cited by 73
“The shift is multifactorial, including premature mortality in the birth cohort [32], persons in the birth cohort treated and cured of their infection [33], and higher incidence of new HCV infections among younger PWID [6].”
Jordan, A. E., Perlman, D. C., Neurer, J., Smith, D. J., Jarlais, D. C. D., & Hagan, H. (2016) · International Journal of STD & AIDS · doi:10.1177/0956462416630910 · Cited by 88
“meta-analyses among PWID generally (43–85%).(65,66) The observation that the pooled HCV prevalence was higher among HIVþMSM who have also injected than among those who have not is consistent with the efficiency of HCV transmission by non-sterile injection.”
ResultEsmaeili, A., Mirzazadeh, A., Carter, G. M., Esmaeili, A., Hajarizadeh, B., Sacks, H. S., & Page, K. A. (2016) · Journal of Viral Hepatitis · doi:10.1111/jvh.12628 · Cited by 77
Valenciano, S. J., Onukwube, J. I., Spiller, M. W., Thomas, A. R., Como-Sabetti, K. J., Schaffner, W., Farley, M. M., Petit, S., Watt, J., Spina, N., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa787 · Cited by 69
“Rate Estimates We calculated the national iGAS infection rate among people with documented IDU during 2011, the most recent year for which a US population estimate was available for this behavior [19].”
Method“I probably got a minute”: Perceptions of fentanyl test strip use among people who use stimulants
Reed, M. K., Roth, A. M., Tabb, L. P., Groves, A. K., & Lankenau, S. E. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103147 · Cited by 65
Barocas, J. A., Eftekhari Yazdi, G., Savinkina, A., Nolen, S., Savitzky, C., Samet, J. H., Englander, H., & Linas, B. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1346 · Cited by 60
“This is particularly relevant with regard to the population-level impact, in which we used older estimates of the prevalence of PWID [15].”
BackgroundMethodInfluentialMiller, A. C., & Polgreen, P. M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy632 · Cited by 56
Larney, S., Mathers, B. M., Poteat, T., Kamarulzaman, A., & Degenhardt, L. J. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000623 · Cited by 65
Gordon, A. (2016) · Journal of Drug Abuse · doi:10.21767/2471-853x.100030 · Cited by 59
Crepaz, N., Hess, K. L., Purcell, D. W., & Hall, H. I. (2018) · AIDS · doi:10.1097/qad.0000000000002111 · Cited by 58
“The denominators: estimated population sizes for MSM, persons who inject drugs, and heterosexuals in the United States We used the previously published estimates of proportions of the US population classified as MSM [2], PWID [3], and heterosexuals [4] (see Appendix A, http:// links.”
Self-citationThe Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham, D. P., Skrip, L., Bruce, R. D., Vilarinho, S., Elbasha, E. H., Galvani, A. P., & Townsend, J. P. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ894 · Cited by 56
“Furthermore, current PWID treatment rates are insufficient to substantially reduce HCV prevalence [12], and low screening rates among the estimated 775 000 PWIDs pose a barrier to treating this high-risk group [13, 14].”
Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States
Hutchinson, A. B., Farnham, P. G., Sansom, S. L., Yaylalı, E., & Mermin, J. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000838 · Cited by 58
“2%) based on 2009 HIV incidence and recent estimates of the IDU population.(23,24)”
BackgroundExpansion of Syringe Service Programs in the United States, 2015–2018
Jarlais, D. C. D., Feelemyer, J. P., LaKosky, P. A., Szymanowski, K., & Arasteh, K. (2020) · American Journal of Public Health · doi:10.2105/ajph.2019.305515 · Cited by 56
Endocarditis as a Marker for New Epidemics of Injection Drug Use
Keeshin, S. W., & Feinberg, J. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.10.002 · Cited by 58
“population; thus, a significant number of individuals are then at risk for IE, and infection with hepatitis C virus (HCV), hepatitis B virus or human immunodeficiency virus (HIV) or with all these.(8) In contrast to non-IDU–associated IE, although PWID have typically been described as presenting with right-sided endoc…”
BackgroundSpringer, S. A., Larney, S., Alammehrjerdi, Z., Altice, F. L., Metzger, D. S., & SHOPTAW, S. J. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000637 · Cited by 62
“6% of the population) have ever injected drugs.(33) Women comprise around one-third of this group.”
BackgroundGender-based vulnerability in women who inject drugs in a harm reduction setting
Valencia, J. A. S., Álvaro‐Meca, A., Troya, J., Gutiérrez, J., Ramón, C., Rodríguez, A., Vázquez‐Morón, S., Resino, S., Moreno, S., & Ryan, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230886 · Cited by 51
“Despite the fact that current drug use is higher among males than females [3], several studies have shown that injection practices among women may put them at a higher risk [4–7].”
BackgroundJordan, A. E., Jarlais, D. C. D., Arasteh, K., McKnight, C. A., Nash, D., & Perlman, D. C. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.03.039 · Cited by 50
“Its transmissibility, combined with a high populaion prevalence among PWID (estimated at 43–67% among lifetime WID; Armstrong et al., 2006; Lansky et al., 2014; World Health rganization, 2014), and a high prevalence of drug injection behavors that facilitate transmission (e.”
BackgroundAn Evaluation of Opioid Use in Black Communities: A Rapid Review of the Literature
Jordan, A., Mathis, M. L., Haeny, A. M., Funaro, M. C., Paltin, D., & Ransome, Y. (2021) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000285 · Cited by 53
“7) of Black people in the United States inject drugs, including amphetamines, cocaine, heroin, or steroids.(10) In U.”
BackgroundBarocas, J. A., Savinkina, A. A., Adams, J. W., Jawa, R., Weinstein, Z., Samet, J. H., & Linas, B. P. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00248-6 · Cited by 51
Jain, M. K., Thamer, M., Therapondos, G., Shiffman, M. L., Kshirsagar, O. S., Clark, C., & Wong, R. J. (2018) · Hepatology · doi:10.1002/hep.30171 · Cited by 50
“6),(19) and the estimated lifetime rate among people who inject drugs (PWID) is 43%.(20) Additionally, treatment of HCV among PWID will lead to a reduction in HCV transmission,(21) which must occur to achieve HCV elimination.”
BackgroundRoth, A. M., Tran, N. K., Piecara, B., Welles, S. L., Shinefeld, J., & Brady, K. T. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2293-0 · Cited by 47
Skin and Soft Tissue Infections in Persons Who Inject Drugs
Chambers, H. F. “. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.10.006 · Cited by 47
Eger, W. H., Abramovitz, D. A., Bazzi, A. R., Bórquez, A., Vera, C. F., Vera, A., Friedman, J. R., & Strathdee, S. A. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111318 · Cited by 46
Impact of Improved HIV Care and Treatment on PrEP Effectiveness in the United States, 2016–2020
Khurana, N., Yaylalı, E., Farnham, P. G., Hicks, K. A., Allaire, B. T., Jacobson, E. U., & Sansom, S. L. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001707 · Cited by 46
“Lansky et al 18 estimated that 0.36% (0.26% – 0.47”
InfluentialArtenie, A. A., Trickey, A., Looker, K. J., Stone, J., Lim, A. G., Fraser, H., Degenhardt, L. J., Dore, G. J., Grebely, J., Cunningham, E. B., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00442-4 · Cited by 56
Horvath, K. J., Lammert, S. M., MacLehose, R. F., Danh, T., Baker, J. V., & Carrico, A. W. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02597-3 · Cited by 46
Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States
Tatar, M., Keeshin, S. W., Mailliard, M. E., & Wilson, F. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.15756 · Cited by 45
Smith, D. K., Pan, Y., Rose, C. E., Pals, S. L., Mehta, S. H., Kirk, G. D., & Herbst, J. H. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000123 · Cited by 41
“In addition, the authors estimated 3648 IDUs in the 50 US states received a diagnosis of HIV infection in 2011 (Lansky et al., 2014).”
BackgroundJarlais, D. C. D., Khuê, P. M., Feelemyer, J. P., Arasteh, K., Hương, D. T., Oanh, K. T. H., Giang, H. T., Thanh, N. T. T., Hai, V. V., Heckathorn, D. D., et al. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.11.033 · Cited by 41
“…including defining membership in the population, biases in the members of key populations who do and do not use services, biases in the members who will or will not participate in research studies, and movement in and out of the population (Brady et al., 2008; Lansky et al., 2014; Xu et al., 2014).”
BackgroundPerlman, D. C., Jordan, A. E., Uusküla, A., Hương, D. T., Masson, C. L., Schackman, B. R., & Jarlais, D. C. D. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.04.015 · Cited by 46
Deida, A. A. V., Shihadeh, K. C., Preslaski, C. R., Young, H. L., Wyles, D. L., & Jenkins, T. C. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa293 · Cited by 40
“Data extracted from the electronic health record included patient demographics, medical comorbidities, microbiology, applyparastyle “fig//caption/p[1]” parastyle “FigCapt””
MethodHepatitis C virus infection spontaneous clearance: Has it been underestimated?
Ayoub, H. H., Chemaitelly, H. S., Omori, R., & Abu-Raddad, L. J. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.07.013 · Cited by 42
Bradley, H. M., Hogan, V., Agnew-Brune, C. B., Armstrong, J., Broussard, D., Buchacz, K. A., Burton, K., Cope, S., Dawson, E. L., Garza, G. D. L., et al. (2019) · Annals of Epidemiology · doi:10.1016/j.annepidem.2019.02.012 · Cited by 39
Mahmud, S., Mumtaz, G. R., Chemaitelly, H. S., Kanaani, Z. A., Kouyoumjian, S. P., Hermez, J. G., & Abu-Raddad, L. J. (2020) · Addiction · doi:10.1111/add.14944 · Cited by 39
“[140] Therefore, the number of chronic infections due to injecting drug use in MENA could be substantially greater than the estimated 221000 for current PWID, although probably not sevenfold higher as it is in the United States, as injecting drug use in this region appears to be more of a recent phenomenon compared to…”
BackgroundFactors associated with being asked to initiate someone into injection drug use
Bluthenthal, R. N., Wenger, L. D., Chu, D., Lorvick, J., Quinn, B., Thing, J., & Kral, A. H. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.02.011 · Cited by 38
“With this in mind, it is likely that the gender difference in initiators as reported by PWID may be explained by the simple fact that PWID are disproportionately male (Lansky et al., 2014; Tempalski et al., 2013).”
BackgroundCorrelates of Injection Drug Use Among Rural Appalachian Women
Staton, M., Ciciurkaite, G., Havens, J. R., Tillson, M. D., Leukefeld, C. G., Webster, J. M., Oser, C. B., & Peteet, B. J. (2017) · The Journal of Rural Health · doi:10.1111/jrh.12256 · Cited by 40
Hall, E. W., Rosenberg, E. S., & Sullivan, P. S. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3133-6 · Cited by 40
“6% for women), which is a risk factor for infection [29].”
BackgroundPopulation Size Estimates for Men who Have Sex with Men and Persons who Inject Drugs
Oster, A. M., Sternberg, M., Lansky, A. L., Broz, D., Wejnert, C., & Paz‐Bailey, G. (2015) · Journal of Urban Health · doi:10.1007/s11524-015-9970-3 · Cited by 36
Self-citationEsmaeili, A., Mirzazadeh, A., Morris, M. D., Hajarizadeh, B., Sacks, H. S., Maher, L., Grebely, J., Kim, A. Y., Lauer, G. M., Cox, A. L., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix768 · Cited by 42
Macias‐Konstantopoulos, W., Heins, A., Sachs, C. J., Whiteman, P. J., Wingkun, N., & Riviello, R. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2020.11.008 · Cited by 40
Escudero, D. J., Lurie, M. N., Mayer, K. H., King, M. R. F., Galea, S., Friedman, S. R., & Marshall, B. D. L. (2017) · BMC Public Health · doi:10.1186/s12889-017-4528-9 · Cited by 34
A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs
Biello, K. B., Edeza, A., Salhaney, P., Biancarelli, D. L., Mimiaga, M. J., Drainoni, M., Childs, E., & Bazzi, A. R. (2019) · AIDS Care · doi:10.1080/09540121.2019.1587356 · Cited by 34
“Currently, the only U.S. FDA-approved formulation of PrEP is a daily oral pill.”
InfluentialPage, K. A., Tsui, J. I., Maher, L., Choopanya, K., Vanichseni, S., Mock, P. A., Celum, C., & Martin, M. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000641 · Cited by 34
“No genderspecific estimates were provided, and most studies included had modest sample sizes with the majority of participants being male, consistent with a male predominance among PWID.(8,9) OAT has also been shown to be effective in preventing HCV.”
BackgroundInfluentialWe know the streets:” race, place, and the politics of harm reduction
Owczarzak, J., Weicker, N., Urquhart, G., Morris, M., Park, J. N., & Sherman, S. G. (2020) · Health & Place · doi:10.1016/j.healthplace.2020.102376 · Cited by 33
Providing reproductive health services for women who inject drugs: a pilot program
Owens, L. E., Gilmore, K. C., Terplan, M., Prager, S., & Micks, E. (2020) · Harm Reduction Journal · doi:10.1186/s12954-020-00395-y · Cited by 35
“3% of Americans 13 years of age and older, representing 750,000 people, injected drugs in the preceding year [1].”
BackgroundWhite, R. H., O’Rourke, A., Kilkenny, M. E., Schneider, K. E., Weir, B. W., Grieb, S. M. D., Sherman, S. G., & Allen, S. T. (2020) · Addiction · doi:10.1111/add.15151 · Cited by 34
“While addressing structural vulnerabilities will take time, increasing individual-level access to harm reduction programs may be an effective strategy for preventing IDU-associated HIV and viral hepatitis outbreaks among PWID living in rural settings.”
BackgroundInfluentialAnderson, E. S., Russell, C., Basham, K., Montgomery, M. E., Lozier, H., Crocker, A., Zuluaga, M., & White, D. A. E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233927 · Cited by 31
“Unfortunately, accurate data is lacking on the number of PWID in the ED, and available studies use probability surveys to estimate utilization or a combination of international classification disease codes to estimate PWID prevalence in various care settings [4,16,17].”
BackgroundJones, J. M., Gurbaxani, B. M., Asher, A. K., Sansom, S. L., Annambhotla, P. D., Moorman, A. C., Kamili, S., Brooks, J. T., & Basavaraju, S. V. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15393 · Cited by 31
Hood, J. E., Golden, M. R., Hughes, J. P., Goodreau, S. M., Siddiqi, A.-E.-A., Buskin, S. E., & Hawes, S. E. (2017) · AIDS Care · doi:10.1080/09540121.2017.1308466 · Cited by 29
“Indeed, existing population estimates suggest that injection drug use (IDU) is more prevalent among NHWhites and NH-Blacks/African Americans than Hispanics and people of other racial/ethnic backgrounds (Lansky et al., 2014), and that IDU is trending downward over time for most sub-groups, except young people who are i…”
BackgroundPage, K., Yu, M. A., Cohen, J., Evans, J. L., Shumway, M., & Riley, E. D. (2017) · BMC Public Health · doi:10.1186/s12889-017-4102-5 · Cited by 29
“Hepatitis C virus (HCV) infection is a widespread and chronic disease that is most prevalent among people who inject drugs (PWID) [1, 2], and which also disproportionately impacts racial and ethnic minorities [3–5], veterans [6], those who are incarcerated [7–9], the poor [10, 11], and unstably housed persons [12, 13].”
BackgroundSalemi, J. L., Spooner, K. K., de Grubb, M. C. M., Aggarwal, A., Matas, J. L., & Salihu, H. M. (2016) · Journal of Medical Virology · doi:10.1002/jmv.24725 · Cited by 28
“Further, given that injection drug use is a primary risk factor for HCV infection [Armstrong et al., 2006], and the highest proportion of injection drug users in the US within the study period were NH-white [Lansky et al., 2014]—this may also explain the higher rates of HCV among NH-whites.”
BackgroundInfluentialJawa, R., Tin, Y., Nall, S. K., Calcaterra, S. L., Savinkina, A. A., Marks, L. R., Kimmel, S. D., Linas, B. P., & Barocas, J. A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.7888 · Cited by 31
Huth, K. B. S., Luigjes, J., Marsman, M., Goudriaan, A. E., & van Holst, R. J. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.107128 · Cited by 28
Gicquelais, R. E., Foxman, B., Coyle, J. R., & Eisenberg, M. C. (2019) · Epidemics · doi:10.1016/j.epidem.2019.02.003 · Cited by 27
Coffin, P. O., Santos, G., Behar, E., Hern, J., Walker, J. E., Matheson, T., Kinnard, E. N., Silvis, J., Vittinghoff, E., Fox, R. K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217471 · Cited by 26
“[2–4] HCV primarily affects people who inject drugs (PWIDs), 43% of whom are believed to be infected.[2,5] Moreover, the current resurgence of HCV in the U.”
BackgroundLuk, J. W., Worley, M. J., Winiger, E. A., Trim, R. S., Hopfer, C. J., Hewitt, J. K., Brown, S. A., & Wall, T. L. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.10.006 · Cited by 28
“Over 10% of the participants reported lifetime injection drug use, whereas the lifetime prevalence of injection drug use was estimated to be 2.6% in the U.S. population aged 13 years or older (Lansky et al., 2014).”
BackgroundInfluentialKarch, D. L., Gray, K. M., Shi, J. C., & Hall, H. I. (2016) · The Open AIDS Journal · doi:10.2174/1874613601610010127 · Cited by 27
“Assess outcomes along the care continuum for HIV-infected people who inject drugs (PWID), by type of facility and stage of infection at diagnosis.”
Williams, L. D., Ibragimov, U., Tempalski, B., Stall, R. D., Johnson, A. S., Wang, G., Cooper, H. L. F., & Friedman, S. R. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.03.011 · Cited by 25
Cooley, L. A., Wejnert, C., Spiller, M. W., Broz, D., & Paz‐Bailey, G. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.05.024 · Cited by 25
“Although PWID who reported injecting within the past 12 months comprised 1% of the U.S. population aged 13 years or older in 2011 (Lansky et al., 2014), injection drug use accounted for an estimated 20% of prevalent infections among persons living with diagnosed HIV infection in the United States…”
BackgroundSelf-citationBradley, H. M., Rosenthal, E. M., Barranco, M. A., Udo, T., Sullivan, P. S., & Rosenberg, E. S. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa318 · Cited by 28
“” Second, questionnaire items could be harmonized across surveys to facilitate meta-analyses that combine data from small samples, as was previously carried out by Lansky and colleagues [25].”
BackgroundGundlach, B. K., Sasor, S. E., & Chung, K. C. (2020) · Hand Clinics · doi:10.1016/j.hcl.2020.03.001 · Cited by 24
To, L., Dunnington, T., Thomas, C., Love, K., McCullough, J., & Riley, W. (2019) · Transfusion · doi:10.1111/trf.15573 · Cited by 24
Lansky, A. L., Johnson, C., Oraka, E., Sionéan, C., Joyce, M. P., DiNenno, E. A., & Crepaz, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133543 · Cited by 23
“The proportion heterosexual among males is lower than among females in part because of exclusions for MSM and for PWID (the proportion PWID is higher among males than females) [3].”
BackgroundMethodInfluentialSelf-citationNovel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs
Coffin, P. O., Rowe, C. L., & Santos, G. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0248-2 · Cited by 24
McGrew, K. M., Carabin, H., Garwe, T., Jafarzadeh, S. R., Williams, M. B., Zhao, Y. D., & Drevets, D. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107906 · Cited by 23
Cooper, H. L. F., Linton, S. L., Kelley, M. E., Ross, Z., Wolfe, M. E., Chen, Y., Zlotorzynska, M., Hunter-Jones, J. J., Friedman, S. R., Jarlais, D. C. D., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150410 · Cited by 24
“In the United States (US) in 2011, estimated rates of newly diagnosed HIV cases among people who inject drugs (PWID) were eleven times as high among black PWID (230/100,000), and six times as high among Latino PWID (121/100,000), as among white PWID (21/100,000) [1].”
BackgroundSelf-citationCooper, H. L. F., West, B. S., Linton, S. L., Hunter-Jones, J. J., Zlotorzynska, M., Stall, R. D., Wolfe, M. E., Williams, L. D., Hall, H. I., Cleland, C. M., et al. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302911 · Cited by 21
Adverse childhood experiences and MSM marijuana use
Giano, Z. D., Hubach, R. D., Currin, J. M., & Wheeler, D. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.024 · Cited by 22
Edeza, A., Bazzi, A. R., Salhaney, P., Biancarelli, D. L., Childs, E., Mimiaga, M. J., Drainoni, M., & Biello, K. B. (2019) · Substance Use & Misuse · doi:10.1080/10826084.2019.1673419 · Cited by 21
“While PWID comprise less than 2.6% of the country’s population, they account for 7-10% of new HIV infections annually (Lansky et al., 2014; Spiller, Broz, Wejnert, Nerlander, & Paz-Bailey, 2015) and 22% of all persons living with HIV (Lansky et al., 2014).”
BackgroundInfluentialUsing medical examiner case narratives to improve opioid overdose surveillance
Hurstak, E., Rowe, C. L., Turner, C., Behar, E., Cabugao, R., Lemos, N. P., Burke, C., & Coffin, P. O. (2018) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.12.017 · Cited by 20
“Obtaining accurate estimates of the number of people who inject drugs is challenging due to multiple methodologic limitations (Lansky et al., 2014), yet recent data suggest increases in the rates of injection of opioid analgesics (Jones, Christensen, & Gladden, 2017).”
BackgroundTran, N. K., Felsher, M. A., Pol, B. J. V. D., Bellamy, S. L., McKnight, J., & Roth, A. M. (2021) · AIDS Care · doi:10.1080/09540121.2021.1874267 · Cited by 20
“…pooled data from nationally representative samples estimated that WWID were 40% more likely than men who inject drugs (MWID) to have a new HIV diagnosis in 2011 (Lansky et al., 2014) despite the higher absolute numbers of new infections among MWID (Center for Disease Control and Prevention, 2018).”
BackgroundUsing technology to assess and intervene with illicit drug-using persons at risk for HIV
Horvath, K. J., Lammert, S. M., LeGrand, S., Muessig, K. E., & Bauermeister, J. A. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000398 · Cited by 20
Assessing the Validity of Data Synthesis Methods to Estimate Religious Populations
de Kramer, R. M., Tighe, E. M., Saxe, L., & Parmer, D. (2018) · Journal for the Scientific Study of Religion · doi:10.1111/jssr.12513 · Cited by 20
HIV Outbreak Control With Effective Access to Care and Harm Reduction in North Carolina, 2017–2018
Samoff, E., Mobley, V., Hudgins, M. K., Cope, A. B., Adams, N. D., Caputo, C. R., Dennis, A. M., Billock, R. M., Crowley, C. A., Clymore, J. M., et al. (2020) · American Journal of Public Health · doi:10.2105/ajph.2019.305490 · Cited by 20
Examining the efficacy of a computer facilitated HIV prevention tool in drug court
Festinger, D. S., Dugosh, K. L., Kurth, A., & Metzger, D. S. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.02.026 · Cited by 19
Infective Endocarditis Secondary to Injection Drug Use: A Survey of Canadian Cardiac Surgeons
An, K. R., Luc, J. G. Y., Tam, D. Y., Dagher, O., Eikelboom, R., Bierer, J. D., Cartier, A., Vo, T. X., Vaillancourt, O., Forgie, K. A., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.12.003 · Cited by 20
Johnson, E. O., Hancock, D. B., Levy, J. L., Gaddis, N., Page, G. P., Glasheen, C., Saccone, N. L., Bierut, L. J., & Kral, A. H. (2015) · Addiction Biology · doi:10.1111/adb.12286 · Cited by 21
“6% of the US population 13 years of age or older has a lifetime history of injecting drugs (Lansky et al. 2014).”
InfluentialMumtaz, G. R., Weiss, H. A., & Abu-Raddad, L. J. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.1.20582 · Cited by 18
“In the United States, for example, the number of HCV-infected previous PWID is more than seven times the number of HCV-infected current PWID [7].”
BackgroundAnnambhotla, P. D., Gurbaxani, B. M., Kuehnert, M. J., & Basavaraju, S. V. (2017) · Transplant Infectious Disease · doi:10.1111/tid.12676 · Cited by 18
Trends and distinct profiles of persons who inject drugs in the United States, 2015–2019
Park, D., Oh, S., Cano, M. N., Salas‐Wright, C. P., & Vaughn, M. G. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107289 · Cited by 17
Blackburn, N. A., Patel, R. C., & Zibbell, J. E. (2016) · Public Health Reports · doi:10.1177/00333549161310s214 · Cited by 17
“Next, we used indicators to evaluate the HCV testing-to-care continuum in the following order: (1) anti-HCV-positive test, (2) HCV RNA test received, (3) HCV RNA-positive test, (4) referred to care, and (5) attended first medical appointment.”
Metadata
- Authors
- Lansky, A., Finlayson, T., Johnson, C., Holtzman, D., Wejnert, C., Mitsch, A., Gust, D., Chen, R., Mizuno, Y., & Crepaz, N.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Lansky, Amy
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-19
- Volume
- 9
- Issue
- 5
- Pages
- e97596
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4026524
- OpenAlex
- W1996627792
- Cited by
- 235
- References
- 23
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 7 · 2023: 15 · 2022: 8 · 2021: 31 · 2020: 36 · 2019: 24 · 2018: 26 · 2017: 30 · 2016: 20 · 2015: 24 · 2014: 1
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- people who inject drugs, HIV infection rates, population size estimation, HIV surveillance, health disparities, United States
- MeSH terms
- Adolescent, Adult, Female, Hepatitis C, Humans, Male, Middle Aged, United States, HIV Infections, Substance Abuse, Intravenous, Drug Users, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
